Needham Maintains Buy on Axsome Therapeutics, Raises Price Target to $267

Benzinga Newsdesk www.benzinga.com Positive 85.3%

Neg 0% Neu 0% Pos 85.3%

Needham analyst Ami Fadia maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and raises the price target from $255 to $267.